Alpha Tau Medical Ltd. (DRTS)

IL — Healthcare Sector
Peers:   EYEN  OCUL  TNYA  INZY  MNOV  ELYM  MOLN  CSBR  CYT  GNFT  ERYP  HCWB 

Automate Your Wheel Strategy on DRTS

With Tiblio's Option Bot, you can configure your own wheel strategy including DRTS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol DRTS
  • Rev/Share 0.0
  • Book/Share 0.894
  • PB 3.2772
  • Debt/Equity 0.2
  • CurrentRatio 7.4039
  • ROIC -0.459

 

  • MktCap 248170121.0
  • FreeCF/Share 0.0
  • PFCF 0.0
  • PE -6.4684
  • Debt/Assets 0.1454
  • DivYield 0
  • ROE -0.4454

 

  • Rating C-
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 2
  • P/B Score 2
  • D/E Score 2

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Alpha Tau to Participate in May Investor Conferences
DRTS
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral

JERUSALEM, May 06, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will presentation in the following investor conferences in May 2025.

Read More
image for news Alpha Tau to Participate in May Investor Conferences
Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical
DRTS, ORMP
Published: April 28, 2025 by: PRNewsWire
Sentiment: Neutral

Oramed leverages its strategic capital markets expertise to support Alpha Tau's breakthrough cancer therapy technology Accelerating multiple late-stage cancer therapies including: US clinical trials across four indications, manufacturing scale-up, and commercialization efforts Partnership unites two innovative therapeutic delivery pioneers – Oramed's oral drug delivery platform with Alpha Tau's precision radiation delivery technology NEW YORK , April 28, 2025 /PRNewswire/ -- Oramed Pharmaceuticals Inc. ("Oramed" or the "Company"), (Nasdaq: ORMP) (TASE: ORMP), a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection, announced today that it has successfully closed a strategic investment in Alpha …

Read More
image for news Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical
Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals
DRTS, ORMP
Published: April 28, 2025 by: GlobeNewsWire
Sentiment: Neutral

JERUSALEM, April 28, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that it has successfully closed a registered direct offering (the “offering”) whereby an affiliate of Oramed Pharmaceuticals Inc. (“Oramed”) (Nasdaq: ORMP) (TASE: ORMP) purchased 14,110,121 of Alpha Tau's ordinary shares, no par value, at a purchase price of $2.612 per ordinary share.

Read More
image for news Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals

About Alpha Tau Medical Ltd. (DRTS)

  • IPO Date 2021-03-08
  • Website https://www.alphatau.com
  • Industry Biotechnology
  • CEO Mr. Uzi Sofer
  • Employees 125

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.